A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Principal Investigator
Kim Nguyen ChiOverview
Study Start/End
Sep 21, 2015 to Feb 28, 2022Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Pam Farish, Study CoordinatorPhone
604-875-4111 ext.68298Email Address
pfarish@prostatecentre.comPurpose of Study
The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.